COMPANY PROFILE / #2107
Invea Therapeutics
Guilford, CTVenture Capital-Backed
OVERVIEW
Invea Therapeutics Inc is a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or Immune-Mediated Inflammatory Diseases. Their pipeline includes INVA8001 which is designed as an oral, small molecule, highly selective and potent inhibitor of chymase, a key mediator of mast cells driving inflammation, epithelial barrier damage and fibrosis and INVA8003 is a de-novo small molecule multi-inflammasome inhibitor that has shown strong inhibition of a key pro-inflammatory marker for several IMIDs in early preclinical testing.
已融资9.79
最新估值109.74
员工数3
成立年份2021
公司概况
- Companies
- Invea Therapeutics
- Description
- Invea Therapeutics Inc is a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or Immune-Mediated Inflammatory Diseases. Their pipeline includes INVA8001 which is designed as an oral, small molecule, highly selective and potent inhibitor of chymase, a key mediator of mast cells driving inflammation, epithelial barrier damage and fibrosis and INVA8003 is a de-novo small molecule multi-inflammasome inhibitor that has shown strong inhibition of a key pro-inflammatory marker for several IMIDs in early preclinical testing.
- Website
- www.inveatx.com
- HQ Location
- Guilford, CT
- Year Founded
- 2021
- Keywords
- ai-powered technology, biotech firm, biotech industry, biotechnology research company, clinical stage biotech, gastrointestinal disorder, small molecule
- Competitors
- Verismo Therapeutics, Cabaletta Bio, Excision
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 9.79
- First Financing Date
- —
- First Financing Size
- 4.24
- First Financing Valuation
- 6.54
- Last Financing Date
- 06-Mar-2026
- Last Financing Deal Type
- IPO
- Last Financing Size
- 35.20
- Last Financing Valuation
- 109.74
- Last Financing Status
- Failed/Cancelled
- Last Known Valuation
- 109.74
- Last Known Valuation Date
- 06-Mar-2026
- Last Known Valuation Deal Type
- IPO
- Valuation Estimate
- 133.82
- Valuation Estimate Growth Rate
- 104.94%
- Active Investors
- Connecticut Innovations
- # Active Investors
- 1
- Acquirers
- —
团队与联系人
- Employees
- 3
- Employee Growth %
- -62.50% E
- Employee History
- 2025: 3, 2024: 8 E, 2023: 12, 2022: 10
- Primary Contact
- Michael Aiello
- Primary Contact Title
- Chief Financial Officer
- Primary Contact Email
- maiello@inveatx.com
- Primary Contact Phone
- +1 (203) 643-8060
增长与经营
- Revenue
- 0.00
- Revenue Growth %
- —
- Growth Rate
- —
- Growth Rate % Change
- —
- Growth Rate Percentile
- —
- Size Multiple
- —
- Size Multiple % Change
- —
- Size Multiple Change
- —
- Size Multiple Percentile
- —
- Majestic Referring Domains
- —
- SimilarWeb Unique Visitors
- —
- SimilarWeb Unique Visitors Change
- —
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- —
- Success Probability Over Time – 3 Year
- —
- Success Probability Over Time – 5 Year
- —
记录来源：public.companies · 原始序号 #2107 · 所有字段均按数据库原值展示。